Matt Kaeberlein
Rapamycin researcher and one of longevity's most honest voices
Bio
Matt Kaeberlein is one of the most respected basic aging researchers of his generation and, increasingly, one of the field's most trusted public communicators. After a long academic career at the University of Washington, he stepped away from tenure to run Optispan, a longevity-focused clinic and media company, while continuing to co-lead the Dog Aging Project.
Background
Kaeberlein trained with Leonard Guarente at MIT during the same sirtuin-era lab that launched several prominent aging researchers. He joined the University of Washington in 2006 and built a lab focused on mTOR signaling, rapamycin, and the comparative biology of aging. He co-founded the Dog Aging Project in 2014 with Daniel Promislow and helped design TRIAD, a rapamycin trial in companion dogs. In 2023 he left UW for Optispan.
What They Do
Kaeberlein runs Optispan, which combines a longevity clinic, a research arm, and a widely listened-to podcast where he candidly discusses what the evidence does and does not support. He continues to co-lead the Dog Aging Project, including PEARL and TRIAD rapamycin trials in dogs. His public communication is unusual in the space for its willingness to push back on hype — including hype from fellow researchers, supplement companies, and biological-age testing services.
Research Record
Kaeberlein has a deep peer-reviewed record on mTOR, rapamycin, and comparative aging biology, including influential papers on rapamycin in yeast, mice, and dogs. He is a frequent contributor to the NIA Interventions Testing Program discussion and is among the most cited researchers in the geroscience field.
Our Evidence Summary
Kaeberlein is arguably the most intellectually honest senior voice in longevity. His core position — that rapamycin is the most compelling geroscience drug in animal models but is not yet ready for routine human use — is well-calibrated to the evidence. He is unusually willing to publicly criticize weak claims, including commercial biological age testing and supplement stacks, even when it is professionally costly.
Claim-by-Claim Evidence Review
Rapamycin extends lifespan in mice across multiple strains and dosing protocols
The NIA Interventions Testing Program has replicated rapamycin's lifespan extension in mice across sites, strains, and timing protocols. This is among the most robust findings in basic aging biology.
Rapamycin extends healthspan in companion dogs
The TRIAD trial and earlier pilot data suggest cardiac and other benefits in middle-aged dogs, but sample sizes are modest and endpoints are still being evaluated. Promising but not definitive.
Rapamycin is ready for routine off-label use as a human longevity drug
Small human trials (PEARL, others) suggest reasonable tolerability at low weekly doses, but no trial has yet shown clinical longevity or major healthspan benefit in humans. Kaeberlein himself is careful to frame this as experimental.
Dogs are a better translational model for human aging than mice
Dogs share our environment, have similar age-related diseases, and have compressed lifespans — all useful features. Whether dog trial results translate more reliably than mouse results to humans is a reasonable hypothesis but unproven.
Commercially available biological age tests are clinically useful for individual decision-making
Kaeberlein has publicly criticized this use case. Noise, test-retest variability, and weak validation make current direct-to-consumer biological age scores poorly suited for guiding individual choices.
mTOR signaling is a central node in the biology of aging
mTOR inhibition extends lifespan across organisms from yeast to mammals. It is one of the clearest conserved aging pathways identified.
Most over-the-counter longevity supplements lack meaningful evidence
Kaeberlein is a vocal skeptic of the supplement industry's longevity claims. This position is well-supported by the scarcity of high-quality human trial data behind most popular products.
Related Reading
The 12 Hallmarks of Aging: A Complete Guide
The 12 hallmarks of aging provide a scientific framework for understanding why we age and where interventions might slow or reverse the process.
Epigenetic Clocks: Measuring Your True Biological Age
Your birthday tells you your chronological age. Epigenetic clocks reveal your biological age — and why the difference matters for longevity science.
Peptides for Longevity: A Science-Based Beginner's Guide
A science-based beginner's guide to peptides for longevity — Epitalon, GHK-Cu, BPC-157, MOTS-c — honest evidence and the regulatory reality.